<DOC>
	<DOCNO>NCT00848107</DOCNO>
	<brief_summary>This open label extension trial allow ongoing treatment subject participate randomize controlled trial , provide long term information safety treprostinil diethanolamine SR subject SSc digital ulcer .</brief_summary>
	<brief_title>Open-Label Study Oral Treprostinil Digital Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Eligible subject complete assessment final visit previous TDEDU201 control trial sign appropriate inform consent eligible enroll extension study . If female childbearing potential , subject must agree continue practice acceptable method birth control ( i.e. , surgical sterilization , approve hormonal contraceptive , barrier method [ condom diaphragm ] use spermicide , intrauterine device ) . Have change clinical status , opinion Investigator , would pose safety risk participation extension study ; Have find unable complete study assessment previous control trial ; Have prematurely discontinue study drug previous study due clinical worsen treatment related adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>digital ulcer</keyword>
	<keyword>vasculopathy</keyword>
</DOC>